GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
GATA3: a multispecific but potentially useful marker in surgical pathology: a systematic analysis of 2500 epithelial and nonepithelial tumors.
复制标题
DOI：
10.1097/pas.0b013e3182a0218f
复制
发表时间：
2014-01
期刊：
影响因子：
--
通讯作者：
Wang Z
中科院分区：
文献类型：
--
作者：
Miettinen M;McCue PA;Sarlomo-Rikala M;Rys J;Czapiewski P;Wazny K;Langfort R;Waloszczyk P;Biernat W;Lasota J;Wang Z
GATA 3是在乳腺上皮细胞、尿道上皮细胞和T淋巴细胞亚群的分化中重要的转录因子。它已被建议在乳腺或尿路上皮起源或转移癌的评价有用，但其在正常和肿瘤组织中的分布是不完全映射。在这项研究中，我们检查了2040上皮和460间充质或神经外胚层肿瘤的正常发育和成人组织中的GATA 3表达，以探讨其在外科病理学中的诊断价值，使用单克隆抗体（克隆L50-823）和Leica Bond自动免疫组化。GATA 3在滋养层、胎儿和成人表皮、成人乳腺和一些唾液腺和汗腺导管上皮、尿道上皮、发育和成人组织中的远端肾单位、一些前列腺基底细胞和T淋巴细胞亚群中表达。在胎儿间皮中表达强于成人，在呼吸道和胃肠道上皮中不表达。在上皮性肿瘤中，GATA 3在>90%的乳腺原发性和转移性导管和小叶癌、尿路上皮和皮肤基底细胞癌以及滋养层和内胚窦肿瘤中表达。在转移性乳腺癌中，它比GCDFP更敏感。在鳞状细胞癌中，表达最高的是皮肤（81%），其次是宫颈（33%）、喉（16%）和肺（12%）肿瘤。常见阳性见于皮肤附属器肿瘤（100%）、间皮瘤（58%）、唾液腺（43%）和胰腺（37%）导管癌，而在肺、胃、结肠、子宫内膜、卵巢和前列腺腺癌中的表达频率<10%。肾嫌色细胞癌是一种独特的肾脏肿瘤，阳性率很高（51%），而嗜酸细胞瘤阳性率为17%，其他类型的阳性率很低。在间叶和神经外胚层肿瘤中，副神经节瘤通常为阳性，这将这些肿瘤与上皮性神经内分泌肿瘤区分开来。间质肿瘤仅零星阳性，除了双相滑膜肉瘤的上皮细胞。GATA 3不仅是乳腺和尿路上皮肿瘤的标志物，也是肾和生殖细胞肿瘤、间皮瘤和副神经节瘤的标志物。当使用该标记物检测转移性乳腺癌或尿路上皮癌时，应考虑GATA 3的多重特异性。
GATA3 is a transcription factor important in the differentiation of breast epithelia, urothelia, and subsets of T-lymphocytes. It has been suggested useful in the evaluation of mammary or urothelial origin or metastatic carcinomas, but its distribution in normal and neoplastic tissues is incompletely mapped. In this study, we examined normal developing and adult tissues in 2040 epithelial and 460 mesenchymal or neuroectodermal neoplasms for GATA3 expression to explore its diagnostic value in surgical pathology, using monoclonal antibody (clone L50-823) and Leica Bond automated immunohistochemistry. GATA3 was expressed in trophoblast, fetal and adult epidermis, adult mammary and some salivary gland and sweat gland ductal epithelia, urothelia, distal nephron in developing and adult tissues, some prostatic basal cells, and subsets of T-lymphocytes. It was expressed stronger in fetal than adult mesothelia and was absent in respiratory and gastrointestinal epithelia. In epithelial neoplasms, GATA3 was expressed in >90% of primary and metastatic ductal and lobular carcinomas of the breast, urothelial, and cutaneous basal cell carcinomas, and trophoblastic and endodermal sinus tumors. In metastatic breast carcinomas, it was more sensitive than GCDFP. Among squamous cell carcinomas, the expression was highest in the skin (81%) and lower in cervical (33%), laryngeal (16%) and pulmonary tumors (12%). Common positivity was found in skin adnexal tumors (100%), mesothelioma (58%), salivary gland (43%) and pancreatic (37%) ductal carcinomas, whereas frequency of expression in adenocarcinomas of lung, stomach, colon, endometrium, ovary, and prostate was <10%. Chromophobe renal cell carcinoma was a unique renal tumor with frequent positivity (51%), whereas oncocytomas were positive in 17% of cases but other types only rarely. Among mesenchymal and neuroectodermal tumors, paragangliomas were usually positive, which sets these tumors apart from epithelial neuroendocrine tumors. Mesenchymal tumors were only sporadically positive, except epithelia of biphasic synovial sarcomas. GATA3 is a useful marker in characterization not only mammary and urothelial but also for renal and germ cell tumors, mesotheliomas, and paragangliomas. The multiple specificities of GATA3 should be taken into account when using this marker to detect metastatic mammary or urothelial carcinomas.